Cargando…

STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer

OBJECTIVES: The intracellular DNA sensor stimulator of interferon genes (STING) has recently been shown to play a vital role in anti-viral and anti-tumor immune responses stimulating cytokine production. While human papillomavirus (HPV) is a causative agent for a subset of head and neck squamous cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Shanhong, Concha-Benavente, Fernando, Shayan, Gulidanna, Srivastava, Raghvendra M., Gibson, Sandra P., Wang, Lin, Gooding, William E., Ferris, Robert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877820/ https://www.ncbi.nlm.nih.gov/pubmed/29496049 http://dx.doi.org/10.1016/j.oraloncology.2018.01.019

Ejemplares similares

PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
por: Concha-Benavente, Fernando, et al.
Publicado: (2015)

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells
por: Concha-Benavente, Fernando, et al.
Publicado: (2014)

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
por: Mazorra, Zaima, et al.
Publicado: (2017)

Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients
por: Li, Jing, et al.
Publicado: (2015)

A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
por: Ferris, Robert L, et al.
Publicado: (2015)

T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response
por: Kansy, Benjamin A., et al.
Publicado: (2018)

EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3
por: Concha-Benavente, Fernando, et al.
Publicado: (2013)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
por: Trivedi, Sumita, et al.
Publicado: (2015)

STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
por: Srivastava, Raghvendra M, et al.
Publicado: (2013)

Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
por: Kansy, Benjamin A, et al.
Publicado: (2015)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model
por: Srivastava, Raghvendra M, et al.
Publicado: (2015)

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT
por: Theodoraki, Marie-Nicole, et al.
Publicado: (2019)

p16, HPV, and Cetuximab: What Is the Evidence?
por: Bonner, James A., et al.
Publicado: (2017)

Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer
por: Juliá, Estefanía Paula, et al.
Publicado: (2020)

Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk
por: Chinnery, Fay, et al.
Publicado: (2012)

TIM-3(+) T cells are not exhausted but activated cells in the tumor microenvironment
por: Jie, Hyun-Bae, et al.
Publicado: (2013)

Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model
por: Chen, Shanshan, et al.
Publicado: (2016)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

Cyclic dinucleotides (CDNs) anti-tumors response by activating DC and NK cell crosstalk
por: Fu, Juan, et al.
Publicado: (2014)

NK-DC Crosstalk in Immunity to Microbial Infection
por: Thomas, Rony, et al.
Publicado: (2016)

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
por: Concha-Benavente, Fernando, et al.
Publicado: (2017)

HBsAg Dampened STING Associated Activation of NK Cells in HBeAg-Negative CHB Patients
por: Zheng, Bingqing, et al.
Publicado: (2021)

STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models
por: Berger, Gilles, et al.
Publicado: (2022)

STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer
por: Da, Yanyan, et al.
Publicado: (2022)

Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation
por: He, Teng, et al.
Publicado: (2022)

Reovirus activated NK cells show enhanced cetuximab mediated antibody-dependent cellular cytotoxicity against colorectal cancer cells
por: Zhao, Xing, et al.
Publicado: (2015)

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15
por: Rocca, Yamila Sol, et al.
Publicado: (2016)

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells
por: Ming Lim, Chwee, et al.
Publicado: (2013)

Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation
por: Milling, Lauren E., et al.
Publicado: (2022)

NK cell-derived IL-10 is critical for DC-NK cell dialogue at the maternal-fetal interface
por: Blois, Sandra M., et al.
Publicado: (2017)

Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer
por: Benavente, Sergi
Publicado: (2023)

STING Mediates Lupus via the Activation of Conventional Dendritic Cell Maturation and Plasmacytoid Dendritic Cell Differentiation
por: Thim-uam, Arthid, et al.
Publicado: (2020)

STING Mediates Lupus via the Activation of Conventional Dendritic Cell Maturation and Plasmacytoid Dendritic Cell Differentiation
por: Thim-uam, Arthid, et al.
Publicado: (2020)

STING activation in cancer immunotherapy
por: Su, Ting, et al.
Publicado: (2019)

Loss of NK Stimulatory Capacity by Plasmacytoid and Monocyte-Derived DC but Not Myeloid DC in HIV-1 Infected Patients
por: Benlahrech, Adel, et al.
Publicado: (2011)

Constitutively Activated DAP12 Induces Functional Anti-Tumor Activation and Maturation of Human Monocyte-Derived DC
por: Dalton, Robert, et al.
Publicado: (2021)

Molecular Regulation of NK Cell Maturation
por: Bi, Jiacheng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ui18b3tor0stdp89hree3ric9a